logo

For the Inventor, By the Inventor

Westfield, NJ, United States of America

Janos Kollonitsch

This inventor holds 18 USPTO granted patents. Top assignee: Merck + Co., Inc.. Active years: 1976-1993.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Janos Kollonitsch. Retrieved from https://idiyas.com/inventor/janos-kollonitsch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 100.0

Average Co-Inventor Count = 1.6

ph-index = 8

Forward Citations = 212(Granted Patents)


Company Filing History:

goldMedal18 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1976-1993

Loading Chart...
18 patents (USPTO):Explore Patents
1. 5227467 - Immunosuppressive fluorinated cyclosporin analogs (1993-07-13),
2. 5030645 - Method of treating asthma using (S)-.alpha.-fluoromethyl-histidine and (1991-07-09),
3. 4695588 - Fluorinated amino acids (1987-09-22),
4. 4483870 - .alpha.-Difluoromethyl amino acids and hypertension treating (1984-11-20),
5. 4431821 - Fluorinated tryptamines (1984-02-14),
6. 4431817 - Fluorinated imidazolyl alkylamines (1984-02-14),
7. 4347374 - Acid addition salts of N-trityl-.alpha.-fluoromethylhistidine enantiomer (1982-08-31),
8. 4325961 - Fluorinated amino acids (1982-04-20),
9. 4292427 - Cephalosporin compounds (1981-09-29),
10. 4288601 - Fluorination process (1981-09-08),
11. 4215221 - Fluorination process (1980-07-29),
12. 4210750 - Process for the preparation of 3-carbamoyl cephalosporins using (1980-07-01),
13. 4096180 - Fluorodehydroxylation of serine (1978-06-20),
14. 4049708 - Fluorodesulfurization of alkyl mercaptans or alkyl dithianes (1977-09-20),
15. 4030994 - Substitutive fluorination of organic compounds (1977-06-21),

Title: Janos Kollonitsch: Innovative Mind Behind Immunosuppressive Therapies

Introduction

Janos Kollonitsch is a prominent inventor located in Westfield, NJ, who has made significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 18 patents, Kollonitsch has focused his research on creating advanced therapies particularly related to immunosuppression and asthma treatment. His work at Merck & Company, Inc. places him among leaders in the pharmaceutical industry.

Latest Patents

Among his latest inventions are innovative immunosuppressive fluorinated cyclosporin analogs. These new analogs feature one or more fluorinated amino acids and can potentially include a 'C-9 amino acid' where the double bond is replaced by a heteroatom, such as sulfur or oxygen. Additionally, he has developed methods for treating asthma using (S)-α-fluoromethyl-histidine. This potent and selective mechanism-based inhibitor targets mammalian histidine carboxylase, the enzyme crucial for histamine biosynthesis in mammals, showing promise in asthma management.

Career Highlights

Throughout his career, Kollonitsch has emerged as a key player in pharmaceutical innovation. His work has led to several patents that not only enhance treatment modalities but also contribute to a better understanding of biochemical pathways involved in disease mechanisms. His dedication to research emphasizes the importance of targeted therapies in improving patient outcomes.

Collaborations

Kollonitsch has collaborated with distinguished colleagues such as Stephen Marburg and Arthur A. Patchett. These partnerships have fostered a collaborative environment that encourages groundbreaking discoveries and reinforces the innovative spirit within Merck & Company, Inc. Such collaborations are pivotal in translating research into practical applications that benefit medical science and patient care.

Conclusion

Janos Kollonitsch stands as a testament to the impact that dedicated inventors can have on healthcare through their innovations. With his extensive patent portfolio and ongoing research efforts, Kollonitsch continues to pave the way for new treatments in immunosuppression and respiratory health, underscoring the critical role of invention in advancing medical therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…